5-溴-2-甲基-3-硝基苯甲酸甲酯 | 220514-28-3

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴-2-甲基-3-硝基苯甲酸甲酯
• 中文别名: 2-甲基-3-硝基-5-溴苯甲酸甲酯
• 英文名称: methyl 5-bromo-2-methyl-3-nitrobenzoate
• 英文别名: methyl 2-methyl-3-bromo-5-nitrobenzoate；5-bromo-2-methyl-3-nitrobenzoic acid methyl ester
• CAS: 220514-28-3
• 化学式: C₉H₈BrNO₄
• mdl: MFCD07781280
• 分子量: 274.071
• InChiKey: UPBDNPCJIJAMPI-UHFFFAOYSA-N

物化性质

• 熔点：
  51.0 to 55.0 °C
• 沸点：
  329.6±37.0 °C(Predicted)
• 密度：
  1.596±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 5-bromo-2-methyl-3-nitrobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-bromo-2-methyl-3-nitrobenzoate
CAS number: 220514-28-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8BrNO4
Molecular weight: 274.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2-甲基-3-硝基苯甲酸甲酯 在 水 、 铁粉 、 sodium carbonate 、 氯化铵 、 溶剂黄146 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 二甲基亚砜 、 1,2-二氯乙烷 为溶剂， 反应 21.2h， 生成 N-[(1,2-二氢-4,6-二甲基-2-氧代-3-吡啶基)甲基]-5-[乙基(四氢-2H-吡喃-4-基)氨基]-4-甲基-4'-(4-吗啉基甲基)-[1,1'-联苯]-3-甲酰胺
  参考文献：
  名称：

  [EN] COMBINATION THERAPY FOR TREATING CANCER
  [FR] POLYTHÉRAPIE ANTICANCÉREUSE

  摘要：

  本发明涉及包含人类组蛋白甲基转移酶EZH2抑制剂和一种或多种其他治疗药物的组合物，特别是抗癌药物如泼尼松，以及用于治疗癌症的组合治疗方法，用于给予需要的受试者。

  公开号：

  WO2013155464A1
• 作为产物：
  描述：

  2-甲基-3-硝基苯甲酸 在 氯化亚砜 、 1,3-二溴-5,5-二甲基海因 作用下， 反应 2.0h， 生成 5-溴-2-甲基-3-硝基苯甲酸甲酯
  参考文献：
  名称：

  X 射线结构引导发现一种有效的口服生物可利用双人吲哚胺/色氨酸 2,3-双加氧酶 (hIDO/hTDO) 抑制剂，该抑制剂在帕金森病小鼠模型中显示出活性

  摘要：

  人吲哚胺 2,3-双加氧酶 1 (hIDO1) 和色氨酸 2,3-双加氧酶 (hTDO) 与帕金森病 (PD) 的发病机制密切相关；然而，仍然缺乏开发 hIDO1 和 hTDO 双重抑制剂来评估其对抗 PD 的潜在功效。在这里，我们报告的生化、生物物理和计算分析表明，1 H -indmaze-4-amines 通过与血红素亚铁和三价铁态直接协调的机制抑制 hIDO1 和 hTDO。晶体结构指导优化得到23 ，其对hIDO1和hTDO的IC 50值分别为0.64和0.04 μM，并且在小鼠中具有良好的药代动力学特性和脑渗透性。 23显示出对 1-甲基-4-苯基-1,2,3,6-四氢吡啶诱导的小鼠运动协调缺陷的功效，与抗 PD 药物美多芭 (Madopar) 相当。进一步的研究表明，与Madopar不同， 23可能具有特定的抗PD机制，包括降低IDO1表达、减轻多巴胺能神经变性、减少小鼠大脑中

  DOI：

  10.1021/acs.jmedchem.1c00303
• 作为试剂：
  描述：

  2-甲基-3-硝基-5-溴苯甲酸 、 disodium;carbonate 、 碘甲烷 在 乙醚 、 5-溴-2-甲基-3-硝基苯甲酸甲酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 以giving desired compound methyl 5-bromo-2-methyl-3-nitrobenzoate (302 g, 99%) which的产率得到5-溴-2-甲基-3-硝基苯甲酸甲酯
  参考文献：
  名称：

  Aryl- or heteroaryl-substituted benzene compounds

  摘要：

  本发明涉及芳基或杂环芳基取代的苯化合物。本发明还涉及包含这些化合物的制药组合物以及通过将这些化合物和制药组合物用于需要这些化合物的受试者治疗癌症的方法。本发明还涉及将这些化合物用于研究或其他非治疗目的的用途。

  公开号：

  US09090562B2

文献信息

• [EN] EZH2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE EZH2 ET LEURS UTILISATIONS
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2015110999A1

  公开（公告）日：2015-07-30

  The present invention provides compound of formula 1, or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, S-oxide or N-oxide thereof. The invention also relates toprocesses for their preparation, to pharmaceutical compositions containing them and use of the compound of formula 1, in the treatment of diseases or disorders mediated by EZH2 (enhancer of zeste homolog 2), particularly cancer.

  本发明提供了式1的化合物，或其同位素形式、立体异构体、互变异构体、药学上可接受的盐、溶剂合物、多晶形态、前药、其S-氧化物或N-氧化物。该发明还涉及它们的制备方法，含有它们的药物组合物以及利用式1的化合物治疗由EZH2（增强子齐斯特同源物2）介导的疾病或紊乱。
• Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma
  作者：Yalin Tu、Yameng Sun、Shuang Qiao、Yao Luo、Panpan Liu、Zhong-Xing Jiang、Yumin Hu、Zifeng Wang、Peng Huang、Shijun Wen

  DOI：10.1021/acs.jmedchem.1c00460

  日期：2021.7.22

  Traditional EZH2 inhibitors are developed to suppress the enzymatic methylation activity, and they may have therapeutic limitations due to the nonenzymatic functions of EZH2 in cancer development. Here, we report proteolysis-target chimera (PROTAC)-based EZH2 degraders to target the whole EZH2 in lymphoma. Two series of EZH2 degraders were designed and synthesized to hijack E3 ligase systems containing

  开发传统的 EZH2 抑制剂是为了抑制酶促甲基化活性，由于 EZH2 在癌症发展中的非酶促功能，它们可能具有治疗局限性。在这里，我们报告了基于蛋白水解靶标嵌合体 (PROTAC) 的 EZH2 降解剂，以靶向淋巴瘤中的整个 EZH2。设计并合成了两个系列的 EZH2 降解剂来劫持包含 von Hippel-Lindau (VHL) 或 cereblon (CRBN) 的 E3 连接酶系统，并且一些基于 VHL 的化合物能够介导 EZH2 降解。两种最好的降解剂 YM181 和 YM281 在弥漫性大 B 细胞淋巴瘤 (DLBCL) 和其他亚型淋巴瘤中诱导强烈的细胞活力抑制，优于临床使用的 EZH2 抑制剂 EPZ6438 (TAzemetosTAt)，后者仅对 DLBCL 有效。EZH2 降解剂在淋巴瘤异种移植物和患者来源的原发性淋巴瘤细胞中显示出有希望的抗肿瘤活性。我们的研究表明，EZH2
• Aryl- or Heteroaryl-Substituted Benzene Compounds
  申请人：KUNTZ KEVIN W.

  公开号：US20120264734A1

  公开（公告）日：2012-10-18

  The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

  本发明涉及芳基或杂芳基取代的苯化合物。本发明还涉及含有这些化合物的药物组合物，以及通过向需要的受试者投与这些化合物和药物组合物来治疗癌症的方法。本发明还涉及利用这些化合物进行研究或其他非治疗目的的用途。
• Preparation Method for Amide Compounds and Use Thereof in Medical Field
  申请人：Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

  公开号：US20220024941A1

  公开（公告）日：2022-01-27

  Provided are a preparation method for amide compounds and use thereof in medical field. Specifically, provided are small molecule amide compounds. Such compounds are inhibitors of enhancer homolog 2 (EZH2) of Zeste gene, and can be used for preventing and/or treating related diseases mediated by EZH2, including tumors, myeloproliferative diseases or autoimmune diseases.

  提供了一种酰胺化合物的制备方法及其在医学领域中的用途。具体来说，提供了小分子酰胺化合物。这些化合物是Zeste基因的增强子同源物2（EZH2）的抑制剂，可用于预防和/或治疗由EZH2介导的相关疾病，包括肿瘤、骨髓增生性疾病或自身免疫疾病。
• ARYL AND HETEROARYL FUSED LACTAMS
  申请人：PFIZER INC.

  公开号：US20140179667A1

  公开（公告）日：2014-06-26

  This invention relates to compounds of general formula (I) in which R 1 , R 2 , U, V, L, M, R 5 , m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

  本发明涉及具有通用公式（I）的化合物，其中R1，R2，U，V，L，M，R5，m，X，Y和Z定义如本文中所述，以及药用可接受的盐，包含此类化合物和盐的药物组合物，以及使用此类化合物、盐和组合物治疗异常细胞生长，包括癌症的方法。

表征谱图